Prescription medication · Anti-IL-4/IL-13 Monoclonal Antibody
dupilumab
Also sold as Dupixent. Dupixent can treat moderate-to-severe atopic dermatitis (eczema) in adults and children 6 months and older.
Data updated 2026-05-15
- 411,692
- FDA reportsHeavily reported
- $1608.24
- Brand price (NADAC)
dupilumab (Dupixent) is a prescription Anti-IL-4/IL-13 Monoclonal Antibody. Dupixent can treat moderate-to-severe atopic dermatitis (eczema) in adults and children 6 months and older.
Dupixent is a medicine that can help treat several conditions. It works by blocking certain proteins in your body that cause inflammation.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$1608.24/unit
Generic Available
No
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Dupixent can treat moderate-to-severe atopic dermatitis (eczema) in adults and children 6 months and older.
Common side effects
Injection site reactions (like redness, swelling, or pain), Conjunctivitis (pink eye), Blepharitis (eyelid inflammation)
Key warnings
Dupixent can cause serious allergic reactions, including anaphylaxis.
The sections below are summarized in plain English from dupilumab's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Dupixent is a type of medicine called a monoclonal antibody. It blocks two proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13). By blocking these proteins, Dupixent helps to reduce inflammation and improve your symptoms.
Side Effects (from patient reports)
Based on 411,692 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for dupilumab, by number of reports
- Pruritus
Pruritus
48,441 reports
- Dermatitis Atopic
Dermatitis Atopic
37,675 reports
- Rash
Rash
33,431 reports
- Injection Site Pain
Injection Site Pain
30,477 reports
- Eczema
Eczema
22,304 reports
- Dry Skin
Dry Skin
21,662 reports
- Condition Aggravated 18,451
Condition Aggravated
18,451 reports
- Arthralgia 16,570
Arthralgia
16,570 reports
- Inappropriate Schedule Of Product Administration 16,307
Inappropriate Schedule Of Product Administration
16,307 reports
- Asthma 13,665
Asthma
13,665 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for dupilumab each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where dupilumab sits
dupilumab has more FDA adverse-event reports than 99% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is dupilumab; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 411,692 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.
Total Reports
411,692
Reports Mentioning Death
1,769
0.4% of reports — not proof of cause
Hospitalization Reports
19,011
Top Indication
Dermatitis Atopic
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | PRURITUS | 48,441 |
| 2 | DERMATITIS ATOPIC | 37,675 |
| 4 | RASH | 33,431 |
| 5 | INJECTION SITE PAIN | 30,477 |
| 7 | ECZEMA | 22,304 |
| 8 | DRY SKIN | 21,662 |
| 10 | CONDITION AGGRAVATED | 18,451 |
| 11 | ARTHRALGIA | 16,570 |
| 12 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 16,307 |
| 13 | ASTHMA | 13,665 |
| 14 | SKIN EXFOLIATION | 12,486 |
| 15 | ACCIDENTAL EXPOSURE TO PRODUCT | 12,191 |
| 16 | ERYTHEMA | 11,817 |
| 18 | DRY EYE | 11,640 |
| 19 | DYSPNOEA | 11,604 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Dupixent can cause serious allergic reactions, including anaphylaxis. Stop using Dupixent and get medical help right away if you have any signs of an allergic reaction. Tell your doctor if you get new or worsening eye problems, such as conjunctivitis or keratitis. Dupixent can sometimes cause eosinophilic conditions, so watch for symptoms like a vasculitic rash, worsening lung symptoms, heart problems, kidney problems, or nerve damage. Do not stop taking steroid medicines suddenly when you start Dupixent. Talk to your doctor about how to slowly lower your steroid dose if needed. Tell your doctor if you develop new psoriasis symptoms or joint symptoms.
Common Questions
What should I tell my doctor before starting Dupixent?
Can I get vaccines while using Dupixent?
What are the most common side effects of Dupixent?
How is Dupixent given?
How often will I need to take Dupixent?
What if I have an allergic reaction to Dupixent?
Can Dupixent be used with other medicines?
What should I do if my symptoms get worse while taking Dupixent?
How long does it take for Dupixent to start working?
Is there a generic version of Dupixent available?
What are the common side effects of dupilumab?
What drug class is dupilumab?
What pregnancy or breastfeeding source fields are listed for dupilumab?
Related Medications in Anti-IL-4/IL-13 Monoclonal Antibody
Other drugs grouped near dupilumab - same-class peers and common alternatives.
aclidinium
Tudorza Pressair
Compare with dupilumab →
albuterol
Ventolin, ProAir
Albuterol is a drug that helps you breathe easier.
Compare with dupilumab →
albuterol/ipratropium
Combivent Respimat, DuoNeb
Combivent Respimat is a combination medicine that helps open your airways.
Compare with dupilumab →
beclomethasone
Qvar
Qvar Redihaler is an inhaled medicine that helps control asthma symptoms.
Compare with dupilumab →
benralizumab
Fasenra
Fasenra is a medicine that can help treat severe asthma and EGPA.
Compare with dupilumab →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for dupilumab: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 411,692.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 0.43%.
- tirzepatide Δ 0.11 pts · 120,921 reports · Dual GIP/GLP-1 Receptor Agonist 0.54%death share
- crisaborole Δ 0.17 pts · 9,400 reports · PDE4 Inhibitor (Topical) 0.26%death share
- etonogestrel Δ 0.23 pts · 46,939 reports · Progestin (Implant) 0.20%death share
- levonorgestrel Δ 0.29 pts · 197,074 reports · Progestin 0.14%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on dupilumab
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for dupilumab
The FDA label for dupilumab (sold under brand names such as Dupixent) classifies it as a prescription-only medication in the Anti-IL-4/IL-13 Monoclonal Antibody class. Dupixent can treat moderate-to-severe atopic dermatitis (eczema) in adults and children 6 months and older. Official labeling lists 27 commonly reported side effects, including Injection site reactions (like redness, swelling, or pain), Conjunctivitis (pink eye), Blepharitis (eyelid inflammation).
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 411,692 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: September 30, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages